Alaunos Therapeutics, Inc.

NasdaqCM:TCRT 株式レポート

時価総額:US$3.3m

Alaunos Therapeutics バランスシートの健全性

財務の健全性 基準チェック /46

Alaunos Therapeuticsの総株主資本は$3.8M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$4.7Mと$907.0Kです。

主要情報

0%

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオn/a
現金US$2.46m
エクイティUS$3.77m
負債合計US$907.00k
総資産US$4.68m

財務の健全性に関する最新情報

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Sep 15

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Aug 31

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Aug 15

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20
Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11
Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09
How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15
We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23
What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

財務状況分析

短期負債: TCRTの 短期資産 ( $4.7M ) が 短期負債 ( $907.0K ) を超えています。

長期負債: TCRTには長期負債はありません。


デット・ツー・エクイティの歴史と分析

負債レベル: TCRTは負債がありません。

負債の削減: TCRT 5 年前には負債がありませんでした。


貸借対照表


キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: TCRTは、現在の フリーキャッシュフロー に基づくと、キャッシュランウェイ が 1 年未満です。

キャッシュランウェイの予測: フリーキャッシュフローが毎年8.9 % の歴史的率で成長し続ける場合、 TCRTのキャッシュランウェイは 1 年未満になります。


健全な企業の発掘